Oticon Alta

Genvec Enters Collaboration on Hearing Loss Treatments with Leading Global Pharmaceutical Company

GAITHERSBURG, MD – January 19, 2010 – GenVec, Inc. (NASDAQ: GNVC) today announced that the company has entered into a research collaboration and license agreement.

GenVec and Novartis will collaborate to discover and develop novel treatments for hearing loss and balance disorders. Preclinical results suggest that delivery of the atonal gene using GenVec’s innovative adenovector technology may have the potential to restore hearing and balance function.

Under terms of the agreement, GenVec is licensing the world-wide rights to its preclinical hearing loss and balance disorders program to Novartis. GenVec will receive a $5 million upfront payment and Novartis has purchased $2 million in GenVec common stock. In addition, GenVec will receive funding from Novartis for a research program focused on developing additional adenovectors for hearing loss. If certain clinical, regulatory and sales milestones are met, GenVec is eligible to receive up to $213.6 million, including upfront and milestone payments, in addition to royalties on future sales.

“Hearing loss is a significant and growing problem for millions of people. Our technology has great promise and this collaboration provides an excellent mechanism to move the development of new treatments forward. We believe Novartis is an ideal collaborator for GenVec. They have the experience, expertise, and resources to develop and commercialize innovative products on a world- wide basis,” said Dr. Paul Fischer, GenVec’s President and Chief Executive Officer.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company’s various filings with the Securities and Exchange Commission.

Share this Article

Comment

Related Content
Preferred Professionals Near You
See More Preferred Professionals

Clinics above not close enough?
Search with your zipcode below.

Sign Up for Our eNewsletter
Our free eNewsletter is delivered to your inbox every two weeks - it’s the best way to stay informed about what’s new at Healthy Hearing!
Preferred Hearing Professionals Near You

Jeffrey H. Aroesty MD, PC

400 Valley Rd Ste 105
Mount Arlington, NJ 07856

Click Here for Details

Total Hearing Care - Hillsborough

311 Courtyard Dr
Hillsborough, NJ 08844

Click Here for Details

ENT and Allergy Associates, LLP - Bridgewater

245 US HWY 22 W 3rd fl
Bridgewater, NJ 08807

Click Here for Details